This Project Grant award of $304,629.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the preclinical development of LCTG-001, a human secretory IgA (sIgA) replacement therapy for patients with Common Variable Immune Deficiency (CVID). The goal is to develop a formulation that can deliver high molecular weight, human polyclonal secretory antibodies directly to mucosal compartments to normalize nasal concentrations of sIgA in CVID patients. This award will fund the development of a nonclinical intranasal pharmacokinetic (PK) profile and formulation framework for LCTG-001 as a novel therapeutic approach to address the respiratory infections and other consequences of IgA deficiency in CVID patients. The project period runs from January 24, 2025 to December 31, 2025.